This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

MERIT-HF trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • this trial assessed the effects of beta-1-blocker metoprolol on patients with heart failure
  • trial design - randomised, double-blind; mean follow-up of one year
  • 3391 patients with chronic heart failure recruited into the study; before randomisation patients also had to be receiving optimal treatment (diuretics with ACE inhibitors)
  • results - of the 1990 treated with metoprolol, 641 patients died or were admitted to hospital as opposed to 767 out of 2001 patients who received placebo. Total mortality or hospitalisation due to heart failure was reduced by one third in the metoprolol group

  • conclusion - the use of metoprolol in patients with chronic heart failure led to a reduced mortality rate and less hospital admissions

Reference:

  • JAMA (2000), 283, 1295-1302.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.